뇌전이(BM) : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 리포트(주요 32 시장) - 2025-2035년

Global Brain Metastasis (BM) Market Outlook

Thelansis's "Global Brain Metastasis (BM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Brain Metastasis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Global Brain Metastasis (BM) Overview

Brain metastasis (BM) represents the most common intracranial malignancy in adults, arising from the hematogenous spread of primary tumors-most frequently from lung, breast, melanoma, and renal cancers-to the central nervous system. Tumor cells infiltrate and colonize brain parenchyma after breaching the blood-brain barrier, leading to rapidly progressive and life-threatening neurological complications.

Clinically, BM is characterized by mass effect and vasogenic edema, resulting in symptoms such as persistent headaches, seizures, cognitive dysfunction, and focal neurological deficits. Diagnosis is primarily contrast-enhanced MRI, which remains the gold standard for detection and treatment planning.

Acute management focuses on rapid symptom stabilization, with corticosteroids (e.g., dexamethasone) used to reduce intracranial edema and improve neurological function. The treatment approach is highly multidisciplinary and personalized, depending on number, size, and location of lesions, as well as systemic disease status.

Local treatment is dominated by stereotactic radiosurgery (SRS) and surgical resection for accessible or symptomatic lesions, while the use of whole-brain radiation therapy (WBRT) has declined due to its association with neurocognitive decline, now reserved for select patients with extensive disease using advanced techniques such as hippocampal avoidance.

The therapeutic landscape has evolved significantly with the advent of CNS-penetrant targeted therapies and immunotherapies, enabling improved intracranial disease control alongside systemic tumor management. Despite these advances, prognosis remains guarded, and BM continues to represent a major unmet need in oncology.

Key Highlights

• Total BM cases are projected to increase from 299,337 in 2025 to 321,620 by 2035, indicating a growing disease burden.
• Rising incidence is driven by improved survival in primary cancers and better detection through advanced imaging.
• Significant clinical burden due to neurological complications and reduced quality of life.
• Treatment paradigm has shifted toward SRS and CNS-active systemic therapies, reducing reliance on WBRT.
• Persistent unmet need in patients with multiple lesions, resistance to therapy, and limited CNS drug penetration.

Market Overview

• The United States BM market is projected to slightly decline from $3.25M to $3.18M, indicating a relatively stable to marginally contracting market.
• Market dynamics are influenced by:
• Shift toward targeted and immunotherapy-based systemic treatments
• Reduced utilization of traditional radiation approaches (WBRT)
• Despite increasing patient numbers, market growth is constrained by treatment consolidation and evolving care pathways.
• Adoption of precision oncology and CNS-penetrant agents is reshaping treatment strategies.
• Future market trends will depend on innovative therapies improving intracranial response and survival outcomes.m to simultaneously eradicate both intracranial and extracranial disease, profoundly extending survival and preserving quality of life.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

30 countries covered:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Blue Earth Diagnostics
• GT Medical Technologies, Inc.
• Radiopharm Theranostics, Ltd
• Allist Pharmaceuticals, Inc.
• UNICANCER
• A2A Pharmaceuticals Inc.
• Medolution Ltd.
• NovoCure GmbH
• MedSIR
• Alpha Biopharma (Jiangsu) Co., Ltd.
• Duke Street Bio Ltd
• Reveal Pharmaceuticals Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)